Hepatocellular Carcinoma SITC CPG Mini Module - Immunotherapy for HCC with Child-Pugh B Cirrhosis

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

Anthony B. El-Khoueiry, MD - USC Norris Cancer Hospital, presents a case on immunotherapy of HCC in a patiaent with alcoholic liver cirrhosis.  Dr. El-Khoueiry then presents data from the GIDEON study and the CheckMate 040 clinical trial to discuss the relationship between liver function and patient outcomes during HCC treatment.  The Q&A session concluding this module includes discussions of using immunotherapy in combination with other local-regional therapies to treat HCC, treating HCC in special paient populations, and the changing landscape of immunotherapy and HCC.

Run time: 16 minutes 49 seconds

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.